Trial · NCT07911020
Psychological and Physiological Effects of Three-Minute Breathing Space Meditation in UPM Postgraduate Students
NCT07911020, Not applicable, Not yet recruiting, ZIRUI LIU
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Psychological and Physiological Effects of Three-Minute Breathing Space Meditation in UPM Postgraduate Students. Trials, record NCT07911020. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911020
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Psychological and Physiological Effects of Three-Minute Breathing Space Meditation in UPM Postgraduate Students
- NCT number
- NCT07911020
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- ZIRUI LIU
- Conditions
- Stress, Anxiety, Depression
- Interventions
- Three-Minute Breathing Space Meditation, Neutral Audio Attention-Control Activity
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in DASS-21 Anxiety Subscale Score | Baseline and Week 8 | The Anxiety subscale of the DASS-21 will be used to assess physiological arousal and subjective anxiety symptoms over the past week. Scores range from 0 to 21, with higher scores indicating greater anxiety severity. |
| Primary | Change in DASS-21 Stress Subscale Score | Baseline and Week 8 | The Stress subscale of the DASS-21 will be used to assess perceived stress over the past week. Scores range from 0 to 21, with higher scores indicating greater stress severity. |
| Primary | Change in DASS-21 Depression Subscale Score | Baseline and Week 8 | The Depression subscale of the DASS-21 will be used to assess dysphoria, hopelessness, and low positive affect over the past week. Scores range from 0 to 21, with higher scores indicating greater depression severity. |
| Secondary | Change in Serum Cortisol | Baseline, Week 4, and Week 8 | Serum cortisol will be measured via venous blood sampling as a biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity and physiological stress response. |
| Secondary | Change in C-Reactive Protein | Baseline, Week 4, and Week 8 | High-sensitivity C-reactive protein (hs-CRP) will be measured via venous blood sampling as a peripheral biomarker of systemic inflammation. |
| Secondary | Change in Frontal Alpha Asymmetry | Baseline, Week 4, and Week 8 | Resting-state electroencephalography (EEG) will be recorded to derive frontal alpha asymmetry, an index of relative left versus right frontal cortical activation associated with approach/withdrawal-related emotional processing. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911020
GET https://conductscience.org/api/trials/v1/NCT07911020/registered